Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Silence Therapeutics (SLN) Other Non Operating Income (2024 - 2025)

Silence Therapeutics (SLN) has disclosed Other Non Operating Income for 2 consecutive years, with $880000.0 as the latest value for Q4 2025.

  • Quarterly Other Non Operating Income rose 131.61% to $880000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$2.8 million through Dec 2025, up 77.32% year-over-year, with the annual reading at $3.5 million for FY2025, 438.7% up from the prior year.
  • Other Non Operating Income hit $880000.0 in Q4 2025 for Silence Therapeutics, down from $1.9 million in the prior quarter.
  • In the past five years, Other Non Operating Income ranged from a high of $1.9 million in Q3 2025 to a low of -$11.4 million in Q3 2024.